Alisertib in Treating Patients With Advanced or Metastatic Sarcoma

NCT01653028 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

72

Enrollment

NIH

Sponsor class

Conditions

Myxofibrosarcoma
Recurrent Adult Soft Tissue Sarcoma
Recurrent Leiomyosarcoma
Recurrent Liposarcoma
Recurrent Malignant Peripheral Nerve Sheath Tumor
Recurrent Undifferentiated Pleomorphic Sarcoma
Stage III Soft Tissue Sarcoma AJCC v7
Stage IV Soft Tissue Sarcoma AJCC v7

Interventions

DRUG: Alisertib
OTHER: Laboratory Biomarker Analysis

Sponsor

National Cancer Institute (NCI)